Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy
Identifieur interne : 004764 ( Main/Merge ); précédent : 004763; suivant : 004765Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy
Auteurs : Alexei Korchounov [Allemagne, Égypte] ; Gregory Bogomazov [Russie]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-12.
English descriptors
- KwdEn :
- Absenteeism, Antiparkinson Agents (therapeutic use), Catechols (therapeutic use), Disability Evaluation, Double-Blind Method, Drug Therapy, Combination, Employment, Female, Humans, Levodopa (therapeutic use), Male, Middle Aged, Nitriles (therapeutic use), Outcome Assessment (Health Care), Parkinson Disease (drug therapy), Parkinson Disease (psychology), Parkinson's disease, Self Concept, dyskinesia, employment, entacapone, retirement.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Catechols, Levodopa, Nitriles.
- drug therapy : Parkinson Disease.
- psychology : Parkinson Disease.
- Absenteeism, Disability Evaluation, Double-Blind Method, Drug Therapy, Combination, Employment, Female, Humans, Male, Middle Aged, Outcome Assessment (Health Care), Self Concept.
Abstract
The objective of this study was to test the impact of entacapone (ENT) addition to levodopa with a decarboxylase inhibitor (LD) in full‐time–employed patients with Parkinson's disease (PD), focusing on retirement rates, medical absenteeism, self‐perception of disability, as well as motor assessments of parkinsonism, motor fluctuations, and dyskinesias. Thirty full‐time–employed PD patients (disease onset before age 60 years) and on optimized monotherapy with LD exhibiting minor motor fluctuations or dyskinesias were entered into a 2‐year randomized double‐blind placebo‐controlled study of ENT adjunctive therapy. The outcome measures were the number of full‐time–employed patients at study end, cumulative days of medical absenteeism, patient‐completed disability assessments, diary records, and the Unified Parkinson's Disease Rating Scale–based measures of motor fluctuations and dyskinesias. LD + ENT treatment was associated with a lower retirement rate (2 [17%] of 12 vs. 6 [50%] of 12; P = 0.12), lower absenteeism rate (21.5 vs. 43.5 days; P < 0.0001), improved self‐perception of disability progression over 2 years (change score 1.0 vs. 4.5; P < 0.0001), and lower scores for both motor fluctuations and dyskinesia assessments compared to LD monotherapy. In this pilot study, LD with ENT adjunctive therapy positively influenced employment rate over 2 years; this effect was associated with reduced motor complications and patient perceptions of stabilized disability. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21123
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001A84
- to stream Istex, to step Curation: 001A84
- to stream Istex, to step Checkpoint: 001F10
- to stream PubMed, to step Corpus: 002A42
- to stream PubMed, to step Curation: 002A42
- to stream PubMed, to step Checkpoint: 002D41
- to stream Ncbi, to step Merge: 001897
- to stream Ncbi, to step Curation: 001897
- to stream Ncbi, to step Checkpoint: 001897
Links to Exploration step
ISTEX:C100D1EB96F2628E5CB83422D95BDD30C8E3D788Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy</title><author><name sortKey="Korchounov, Alexei" sort="Korchounov, Alexei" uniqKey="Korchounov A" first="Alexei" last="Korchounov">Alexei Korchounov</name></author><author><name sortKey="Bogomazov, Gregory" sort="Bogomazov, Gregory" uniqKey="Bogomazov G" first="Gregory" last="Bogomazov">Gregory Bogomazov</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C100D1EB96F2628E5CB83422D95BDD30C8E3D788</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.21123</idno><idno type="url">https://api.istex.fr/document/C100D1EB96F2628E5CB83422D95BDD30C8E3D788/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001A84</idno><idno type="wicri:Area/Istex/Curation">001A84</idno><idno type="wicri:Area/Istex/Checkpoint">001F10</idno><idno type="wicri:doubleKey">0885-3185:2006:Korchounov A:employment:medical:absenteeism</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17044084</idno><idno type="wicri:Area/PubMed/Corpus">002A42</idno><idno type="wicri:Area/PubMed/Curation">002A42</idno><idno type="wicri:Area/PubMed/Checkpoint">002D41</idno><idno type="wicri:Area/Ncbi/Merge">001897</idno><idno type="wicri:Area/Ncbi/Curation">001897</idno><idno type="wicri:Area/Ncbi/Checkpoint">001897</idno><idno type="wicri:doubleKey">0885-3185:2006:Korchounov A:employment:medical:absenteeism</idno><idno type="wicri:Area/Main/Merge">004764</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy</title><author><name sortKey="Korchounov, Alexei" sort="Korchounov, Alexei" uniqKey="Korchounov A" first="Alexei" last="Korchounov">Alexei Korchounov</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Parkinson Clinic, Bad Nauheim</wicri:regionArea><wicri:noRegion>Bad Nauheim</wicri:noRegion><wicri:noRegion>Bad Nauheim</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Égypte</country><wicri:regionArea>Hospital of Misr International University, Cairo</wicri:regionArea><wicri:noRegion>Cairo</wicri:noRegion></affiliation></author><author><name sortKey="Bogomazov, Gregory" sort="Bogomazov, Gregory" uniqKey="Bogomazov G" first="Gregory" last="Bogomazov">Gregory Bogomazov</name><affiliation wicri:level="3"><country xml:lang="fr">Russie</country><wicri:regionArea>Center for Investigation of Movement Disorders, Moscow</wicri:regionArea><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-12">2006-12</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="2220">2220</biblScope><biblScope unit="page" to="2224">2224</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C100D1EB96F2628E5CB83422D95BDD30C8E3D788</idno><idno type="DOI">10.1002/mds.21123</idno><idno type="ArticleID">MDS21123</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Absenteeism</term><term>Antiparkinson Agents (therapeutic use)</term><term>Catechols (therapeutic use)</term><term>Disability Evaluation</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Employment</term><term>Female</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Nitriles (therapeutic use)</term><term>Outcome Assessment (Health Care)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Parkinson's disease</term><term>Self Concept</term><term>dyskinesia</term><term>employment</term><term>entacapone</term><term>retirement</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Catechols</term><term>Levodopa</term><term>Nitriles</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Absenteeism</term><term>Disability Evaluation</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Employment</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Outcome Assessment (Health Care)</term><term>Self Concept</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study was to test the impact of entacapone (ENT) addition to levodopa with a decarboxylase inhibitor (LD) in full‐time–employed patients with Parkinson's disease (PD), focusing on retirement rates, medical absenteeism, self‐perception of disability, as well as motor assessments of parkinsonism, motor fluctuations, and dyskinesias. Thirty full‐time–employed PD patients (disease onset before age 60 years) and on optimized monotherapy with LD exhibiting minor motor fluctuations or dyskinesias were entered into a 2‐year randomized double‐blind placebo‐controlled study of ENT adjunctive therapy. The outcome measures were the number of full‐time–employed patients at study end, cumulative days of medical absenteeism, patient‐completed disability assessments, diary records, and the Unified Parkinson's Disease Rating Scale–based measures of motor fluctuations and dyskinesias. LD + ENT treatment was associated with a lower retirement rate (2 [17%] of 12 vs. 6 [50%] of 12; P = 0.12), lower absenteeism rate (21.5 vs. 43.5 days; P < 0.0001), improved self‐perception of disability progression over 2 years (change score 1.0 vs. 4.5; P < 0.0001), and lower scores for both motor fluctuations and dyskinesia assessments compared to LD monotherapy. In this pilot study, LD with ENT adjunctive therapy positively influenced employment rate over 2 years; this effect was associated with reduced motor complications and patient perceptions of stabilized disability. © 2006 Movement Disorder Society</div></front></TEI><double doi="10.1002/mds.21123"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy</title><author><name sortKey="Korchounov, Alexei" sort="Korchounov, Alexei" uniqKey="Korchounov A" first="Alexei" last="Korchounov">Alexei Korchounov</name></author><author><name sortKey="Bogomazov, Gregory" sort="Bogomazov, Gregory" uniqKey="Bogomazov G" first="Gregory" last="Bogomazov">Gregory Bogomazov</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C100D1EB96F2628E5CB83422D95BDD30C8E3D788</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.21123</idno><idno type="url">https://api.istex.fr/document/C100D1EB96F2628E5CB83422D95BDD30C8E3D788/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001A84</idno><idno type="wicri:Area/Istex/Curation">001A84</idno><idno type="wicri:Area/Istex/Checkpoint">001F10</idno><idno type="wicri:doubleKey">0885-3185:2006:Korchounov A:employment:medical:absenteeism</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy</title><author><name sortKey="Korchounov, Alexei" sort="Korchounov, Alexei" uniqKey="Korchounov A" first="Alexei" last="Korchounov">Alexei Korchounov</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Parkinson Clinic, Bad Nauheim</wicri:regionArea><wicri:noRegion>Bad Nauheim</wicri:noRegion><wicri:noRegion>Bad Nauheim</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Égypte</country><wicri:regionArea>Hospital of Misr International University, Cairo</wicri:regionArea><wicri:noRegion>Cairo</wicri:noRegion></affiliation></author><author><name sortKey="Bogomazov, Gregory" sort="Bogomazov, Gregory" uniqKey="Bogomazov G" first="Gregory" last="Bogomazov">Gregory Bogomazov</name><affiliation wicri:level="3"><country xml:lang="fr">Russie</country><wicri:regionArea>Center for Investigation of Movement Disorders, Moscow</wicri:regionArea><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-12">2006-12</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="2220">2220</biblScope><biblScope unit="page" to="2224">2224</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C100D1EB96F2628E5CB83422D95BDD30C8E3D788</idno><idno type="DOI">10.1002/mds.21123</idno><idno type="ArticleID">MDS21123</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>dyskinesia</term><term>employment</term><term>entacapone</term><term>retirement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study was to test the impact of entacapone (ENT) addition to levodopa with a decarboxylase inhibitor (LD) in full‐time–employed patients with Parkinson's disease (PD), focusing on retirement rates, medical absenteeism, self‐perception of disability, as well as motor assessments of parkinsonism, motor fluctuations, and dyskinesias. Thirty full‐time–employed PD patients (disease onset before age 60 years) and on optimized monotherapy with LD exhibiting minor motor fluctuations or dyskinesias were entered into a 2‐year randomized double‐blind placebo‐controlled study of ENT adjunctive therapy. The outcome measures were the number of full‐time–employed patients at study end, cumulative days of medical absenteeism, patient‐completed disability assessments, diary records, and the Unified Parkinson's Disease Rating Scale–based measures of motor fluctuations and dyskinesias. LD + ENT treatment was associated with a lower retirement rate (2 [17%] of 12 vs. 6 [50%] of 12; P = 0.12), lower absenteeism rate (21.5 vs. 43.5 days; P < 0.0001), improved self‐perception of disability progression over 2 years (change score 1.0 vs. 4.5; P < 0.0001), and lower scores for both motor fluctuations and dyskinesia assessments compared to LD monotherapy. In this pilot study, LD with ENT adjunctive therapy positively influenced employment rate over 2 years; this effect was associated with reduced motor complications and patient perceptions of stabilized disability. © 2006 Movement Disorder Society</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy.</title><author><name sortKey="Korchounov, Alexei" sort="Korchounov, Alexei" uniqKey="Korchounov A" first="Alexei" last="Korchounov">Alexei Korchounov</name><affiliation wicri:level="1"><nlm:affiliation>Parkinson Clinic, Bad Nauheim, Germany. a.korchounov@parkinsonzentrum.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Parkinson Clinic, Bad Nauheim</wicri:regionArea><wicri:noRegion>Bad Nauheim</wicri:noRegion><wicri:noRegion>Bad Nauheim</wicri:noRegion><wicri:noRegion>Bad Nauheim</wicri:noRegion></affiliation></author><author><name sortKey="Bogomazov, Gregory" sort="Bogomazov, Gregory" uniqKey="Bogomazov G" first="Gregory" last="Bogomazov">Gregory Bogomazov</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1002/mds.21123</idno><idno type="RBID">pubmed:17044084</idno><idno type="pmid">17044084</idno><idno type="wicri:Area/PubMed/Corpus">002A42</idno><idno type="wicri:Area/PubMed/Curation">002A42</idno><idno type="wicri:Area/PubMed/Checkpoint">002D41</idno><idno type="wicri:Area/Ncbi/Merge">001897</idno><idno type="wicri:Area/Ncbi/Curation">001897</idno><idno type="wicri:Area/Ncbi/Checkpoint">001897</idno><idno type="wicri:doubleKey">0885-3185:2006:Korchounov A:employment:medical:absenteeism</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy.</title><author><name sortKey="Korchounov, Alexei" sort="Korchounov, Alexei" uniqKey="Korchounov A" first="Alexei" last="Korchounov">Alexei Korchounov</name><affiliation wicri:level="1"><nlm:affiliation>Parkinson Clinic, Bad Nauheim, Germany. a.korchounov@parkinsonzentrum.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Parkinson Clinic, Bad Nauheim</wicri:regionArea><wicri:noRegion>Bad Nauheim</wicri:noRegion><wicri:noRegion>Bad Nauheim</wicri:noRegion><wicri:noRegion>Bad Nauheim</wicri:noRegion></affiliation></author><author><name sortKey="Bogomazov, Gregory" sort="Bogomazov, Gregory" uniqKey="Bogomazov G" first="Gregory" last="Bogomazov">Gregory Bogomazov</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Absenteeism</term><term>Antiparkinson Agents (therapeutic use)</term><term>Catechols (therapeutic use)</term><term>Disability Evaluation</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Employment</term><term>Female</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Nitriles (therapeutic use)</term><term>Outcome Assessment (Health Care)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Self Concept</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Catechols</term><term>Levodopa</term><term>Nitriles</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Absenteeism</term><term>Disability Evaluation</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Employment</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Outcome Assessment (Health Care)</term><term>Self Concept</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study was to test the impact of entacapone (ENT) addition to levodopa with a decarboxylase inhibitor (LD) in full-time-employed patients with Parkinson's disease (PD), focusing on retirement rates, medical absenteeism, self-perception of disability, as well as motor assessments of parkinsonism, motor fluctuations, and dyskinesias. Thirty full-time-employed PD patients (disease onset before age 60 years) and on optimized monotherapy with LD exhibiting minor motor fluctuations or dyskinesias were entered into a 2-year randomized double-blind placebo-controlled study of ENT adjunctive therapy. The outcome measures were the number of full-time-employed patients at study end, cumulative days of medical absenteeism, patient-completed disability assessments, diary records, and the Unified Parkinson's Disease Rating Scale-based measures of motor fluctuations and dyskinesias. LD + ENT treatment was associated with a lower retirement rate (2 [17%] of 12 vs. 6 [50%] of 12; P = 0.12), lower absenteeism rate (21.5 vs. 43.5 days; P < 0.0001), improved self-perception of disability progression over 2 years (change score 1.0 vs. 4.5; P < 0.0001), and lower scores for both motor fluctuations and dyskinesia assessments compared to LD monotherapy. In this pilot study, LD with ENT adjunctive therapy positively influenced employment rate over 2 years; this effect was associated with reduced motor complications and patient perceptions of stabilized disability.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004764 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004764 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:C100D1EB96F2628E5CB83422D95BDD30C8E3D788
|texte= Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy
}}
| This area was generated with Dilib version V0.6.23. |  |